Brawn Biotech (530207)
TurnaroundScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹24.8 |
| Market Cap | ₹7.82 Cr |
| P/E Ratio | 0 |
| ROCE | -42.52% |
| ROE | -3.24% |
| Dividend Yield | 0% |
| Profit Growth | 111.63% |
| Debt/Equity | — |
| Sales Growth | 12.24% |
| 52-Week Range | ₹17.71 — ₹24.8 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹15.45 |
Strengths
- Sales growth of 12.24% shows some revenue momentum.
- Reported profit growth of 111.63% suggests possible earnings recovery from a low base.
- Book value of ₹15.45 provides a tangible asset base against the ₹24.80 price.
- Piotroski F-score of 6/9 indicates moderate fundamental improvement.
Concerns
- ROE at -3.24% and ROCE at -42.52% reflect poor capital allocation.
- Latest quarter net profit is ₹0 Cr, meaning current earnings are absent.
- P/E of 0.00 is meaningless and the stock trades at 1.61 times book without returns.
- Promoter holding and debt/equity are N/A, creating transparency risk.
AI Analysis
At ₹24.80, Brawn Biotech has a market cap of just ₹8 crore. In Graham's language, small size is not a margin of safety. The latest quarter reports sales of ₹4 crore and net profit of ₹0 crore; the trailing P/E shows 0.00, which tells me current earnings do not exist. Sales growth of 12.24% is nice but meaningless if the bottom line is zero. ROE is -3.24% and ROCE is -42.52%; that is capital destruction. The 111.63% profit growth is a statistical illusion from a very low or negative base. Book value is ₹15.45, so at ₹24.80 I am paying 1.61 times book for a business that earns negative returns on equity. There is no dividend, and with promoter holding and debt/equity both listed as N/A, I cannot properly assess governance or leverage. The Piotroski F-score of 6/9 offers some sign of operational improvement, but it is not a substitute for actual earnings. Is there a moat? I see no evidence of pricing power or durable advantage in the pharma space from these numbers. This is a watchlist candidate at best, not an investment. I want a business with predictable earnings, high returns on capital, and management I can trust. Brawn Biotech fails all tests at this price. If it continues to grow sales and converts those sales into consistent positive net profit, with ROE turning positive, I might revisit. But as of now, the risk/reward is unattractive.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer